VCAM: Vascular cell adhesion molecule, VEGF: Vascular Endothelial Growth Factor. References 1. Firestein GS: Evolving concepts of rheumatoid arthritis, Nature, vol.423, pp.356-361, 2003. ,
, Cells of the synovium in rheumatoid arthritis. Chondrocytes, vol.9, p.220, 2007.
Tumor necrosis factor-alpha blockade: a novel therapy for rheumatic disease, Clin Immunol, vol.103, pp.231-242, 2002. ,
Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?, Annu Rev Immunol, vol.19, pp.163-196, 2001. ,
Aggrecan is degraded by matrix metalloproteinases in human arthritis. Evidence that matrix metalloproteinase and aggrecanase activities can be independent, J Clin Invest, vol.98, pp.2292-2299, 1996. ,
Structure and function of aggrecan, Cell Res, vol.12, pp.19-32, 2002. ,
The structure of aggrecan and its turnover in cartilage, J Rheumatol Suppl, vol.43, pp.86-90, 1995. ,
Proteoglycans of the extracellular environment: clues from the gene and protein side offer novel perspectives in molecular diversity and function, FASEB J, vol.10, pp.598-614, 1996. ,
Cartilage destruction in collagen induced arthritis assessed with a new biochemical marker for collagen type II C-telopeptide fragments, J Rheumatol, vol.31, pp.1174-1179, 2004. ,
Relative contribution of matrix metalloprotease and cysteine protease activities to cytokine-stimulated articular cartilage degradation, Osteoarthritis Cartilage, vol.14, pp.738-748, 2006. ,
Generation and novel distribution of matrix metalloproteinase-derived aggrecan fragments in porcine cartilage explants, J Biol Chem, vol.275, pp.33027-33037, 2000. ,
MMP and non-MMP-mediated release of aggrecan and its fragments from articular cartilage: a comparative study of three different aggrecan and glycosaminoglycan assays, Osteoarthritis Cartilage, vol.15, pp.212-221, 2007. ,
Clinical and laboratory assessments in rheumatoid arthritis and osteoarthritis, Br J Rheumatol, vol.35, pp.6-9, 1996. ,
Uncoupling of type II collagen synthesis and degradation predicts progression of joint damage in patients with knee osteoarthritis, Arthritis Rheum, vol.46, pp.2613-2624, 2002. ,
Variability in knee radiographing: implication for definition of radiological progression in medial knee osteoarthritis, Ann Rheum Dis, vol.57, pp.624-629, 1998. ,
The relationship between serial measures of disease activity and outcome in rheumatoid arthritis, Q J Med, vol.86, pp.601-607, 1993. ,
Relationship between time-integrated C-reactive protein levels and radiologic progression in patients with rheumatoid arthritis, Arthritis Rheum, vol.43, pp.1473-1477, 2000. ,
Serum matrix metalloproteinase 3 levels in comparison to C-reactive protein in periods with and without progression of radiological damage in patients with early rheumatoid arthritis, Clin Exp Rheumatol, vol.21, pp.465-472, 2003. ,
Serum matrix metalloproteinase 3 as a predictor of the degree of joint destruction during the six months after measurement, in patients with early rheumatoid arthritis, Arthritis Rheum, vol.43, pp.852-858, 2000. ,
Molecular basis and clinical use of biochemical markers of bone, cartilage, and synovium in joint diseases, Arthritis Rheum, vol.43, pp.953-968, 2000. ,
YKL-40 in giant cells and macrophages from patients with giant cell arteritis, Arthritis Rheum, vol.42, pp.2624-2630, 1999. ,
Methods of assessing radiographic change in rheumatoid arthritis, Am J Med, vol.75, pp.35-47, 1983. ,
Molecular pathology and pathobiology of osteoarthritic cartilage, Cell Mol Life Sci, vol.59, pp.5-18, 2002. ,
Development and characterization of a highly specific and sensitive sandwich ELISA for detection of aggrecanase-generated aggrecan fragments, Osteoarthritis Cartilage, vol.14, pp.702-713, 2006. ,
Lysophospholipids enhance matrix metalloproteinase-2 expression in human endothelial cells, p.400 ,
Induction of increased cAMP levels in articular chondrocytes blocks matrix metalloproteinase-mediated cartilage degradation, but not aggrecanase-mediated cartilage degradation, Arthritis Rheum, vol.56, pp.1549-1558, 2007. ,
Anti-cyclic citrullinated peptide autoantibodies measured by an automated enzyme immunoassay: analytical performance and clinical correlations, Clin Chim Acta, vol.355, pp.137-144, 2005. ,
Towards a molecular understanding of arthritis, Chem Biol, vol.6, pp.157-166, 1999. ,
The role of cytokines as inflammatory mediators in osteoarthritis: lessons from animal models, Connect Tissue Res, vol.40, pp.1-11, 1999. ,
The structure of aggrecan fragments in human synovial fluid. Evidence for the involvement in osteoarthritis of a novel proteinase which cleaves the Glu 373-Ala 374 bond of the interglobular domain, J Clin Invest, vol.89, pp.1512-1516, 1992. ,
Inhibition of ADAM-TS4 and ADAM-TS5 prevents aggrecan degradation in osteoarthritic cartilage, J Biol Chem, vol.277, pp.22201-22208, 2002. ,
Human osteoarthritis synovial fluid and joint cartilage contain both aggrecanase-and matrix metalloproteinase-generated aggrecan fragments, Osteoarthritis Cartilage, vol.14, pp.101-113, 2006. ,
Aggrecanase versus matrix metalloproteinases in the catabolism of the interglobular domain of aggrecan in vitro, Biochem J, vol.344, pp.61-68, 1999. ,
The mechanism of aggrecan release from cartilage differs with tissue origin and the agent used to stimulate catabolism, Biochem J, vol.362, pp.465-472, 2002. ,
Release of hyaluronan and hyaladherins (aggrecan G1 domain and link proteins) from articular cartilage exposed to ADAMTS-4 (aggrecanase 1) or ADAMTS-5 (aggrecanase 2), Arthritis Rheum, vol.50, pp.2839-2848, 2004. ,
Cartilage degradation independent of MMP/aggrecanases, Osteoarthritis Cartilage, vol.12, pp.1006-1014, 2004. ,
The national data base of the German Collaborative Arthritis Centres: I. Structure, aims, and patients, Ann Rheum Dis, vol.60, pp.199-206, 2001. ,